{"id":560790,"date":"2026-08-04T22:52:09","date_gmt":"2026-08-04T20:52:09","guid":{"rendered":"https:\/\/medizinonline.com\/?p=560790"},"modified":"2026-08-04T22:52:22","modified_gmt":"2026-08-04T20:52:22","slug":"ya-esta-disponible-el-primer-inhibidor-de-la-aldosterona-sintasa","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/ya-esta-disponible-el-primer-inhibidor-de-la-aldosterona-sintasa\/","title":{"rendered":"Ya est\u00e1 disponible el primer inhibidor de la aldosterona sintasa"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Se trata de la primera clase nueva de f\u00e1rmacos antihipertensivos en muchos a\u00f1os: el 18 de mayo de 2026, la Agencia Estadounidense de Medicamentos y Alimentos (FDA) autoriz\u00f3 el Baxdrostat (Baxfendy) como el primer y \u00fanico inhibidor de la aldosterona sintasa para el tratamiento de la hipertensi\u00f3n. Esta sustancia act\u00faa sobre una de las causas fundamentales de la hipertensi\u00f3n dif\u00edcil de controlar \u2014la producci\u00f3n excesiva de aldosterona\u2014 y reduce la presi\u00f3n arterial en aquellos casos en los que los f\u00e1rmacos habituales suelen llegar a sus l\u00edmites. La autorizaci\u00f3n se basa en el ensayo de fase III BaxHTN, complementado por el ensayo Bax24 sobre la medici\u00f3n de la presi\u00f3n arterial durante 24 horas en casos de hipertensi\u00f3n resistente. Adem\u00e1s, con el lorundrostat como segundo inhibidor de la aldosterona sintasa y el zilebesiran como enfoque basado en el ARN, se perfila toda una nueva ola de principios terap\u00e9uticos.     <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fya-esta-disponible-el-primer-inhibidor-de-la-aldosterona-sintasa%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Se trata de la primera clase nueva de f\u00e1rmacos antihipertensivos en muchos a\u00f1os: el 18 de mayo de 2026, la Agencia Estadounidense de Medicamentos y Alimentos (FDA) autoriz\u00f3 el Baxdrostat&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fya-esta-disponible-el-primer-inhibidor-de-la-aldosterona-sintasa%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":560791,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Baxdrostat: una nueva clase de f\u00e1rmacos contra la hipertensi\u00f3n dif\u00edcil de controlar","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11552,11324,11475,11408,11478,11288],"tags":[95531,13378,95532],"powerkit_post_featured":[],"class_list":["post-560790","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-es","category-cardiologia","category-estudios","category-farmacologia-y-toxicologia","category-formacion-continua","category-medicina-interna-general","tag-baxdrostat","tag-hipertension","tag-inhibidores-de-la-aldosterona-sintasa","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-08-23 23:26:26","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=560790"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560790\/revisions"}],"predecessor-version":[{"id":560792,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560790\/revisions\/560792"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/560791"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=560790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=560790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=560790"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=560790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}